Results 41 to 50 of about 69,829 (275)

Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study examines the impact of hepatitis C virus (HCV) eradication through sofosbuvir/velpatasvir (SOF/VEL) treatment on glycated hemoglobin (HbA1c) levels in patients with chronic hepatitis C and type 2 diabetes mellitus (T2DM). Utilizing data from the Taiwan HCV Registry, a retrospective analysis was conducted on 2180 patients who met the
Szu‐Jen Wang, Te‐Sheng Chang, Ching‐Chu Lo, Chao‐Hung Hung, Chien‐Wei Huang, Lee‐Won Chong, Pin‐Nan Cheng, Ming‐Jong Bair, Ming‐Lun Yeh, Cheng‐Yuan Peng, Chien‐Yu Cheng, Jee‐Fu Huang, Chih‐Lang Lin, Chi‐Chieh Yang, Hsing‐Tao Kuo, Tsai‐Yuan Hsieh, Tzong‐Hsi Lee, Pei‐Lun Lee, Wen‐Chih Wu, Chih‐Lin Lin, Wei‐Wen Su, Sheng‐Shun Yang, Chia‐Chi Wang, Jui‐Ting Hu, Lein‐Ray Mo, Chun‐Ting Chen, Yi‐Hsiang Huang, Chun‐Chao Chang, Chia‐Sheng Huang, Guei‐Ying Chen, Chien‐Neng Kao, Chi‐Ming Tai, Chun‐Jen Liu, Mei‐Hsuan Lee, Pei‐Chien Tsai, Shu‐Chi Wang, Chia‐Yen Dai, Jia‐Horng Kao, Han‐Chieh Lin, Wang‐Long Chuang, Kuo‐Chih Tseng, Chi‐Yi Chen, Chung‐Feng Huang, Ming‐Lung Yu   +43 more
wiley   +1 more source

Ribavirin and its analogs: Сan you teach an old dog new tricks?

Тонкие химические технологии, 2019
The review article focuses on the current state of synthetic and biological studies of ribavirin analogs. Ribavirin is a broad-spectrum nucleoside antiviral drug with a 50-year long history of research and application, but its mechanism of action still ...
M. V. Chudinov
doaj   +1 more source

Crystallization Selectivity of Ribavirin Solution and Amorphous Phase

Molecules, 2023
Crystallization selectivity is an important principle in polymorph control. Ribavirin Form I, Form II, DMSO solvate, and amorphous ribavirin are prepared, and the short-range order similarities between these solid forms and ribavirin aqueous solution and
Fuying Li, Shiying Chen, Haoxin Hu, Chengfeng Liang, Shiyu Sun, Can Jin, Fenghua Chen   +6 more
doaj   +1 more source

SOFOSBUVIR AND RIBAVIRIN

The Professional Medical Journal, 2018
Objectives: This study was conducted to evaluate the 16-weeks versus 24-weeks efficacy of sofosbuvir and ribavirin in HCV genotype-3a infection. Study Design: Open labeled, single center, longitudinal study. Setting: Khyber Medical College and Khyber Teaching Hospital, Peshawar.
Abid Shah, Nizamud din, Jamalud Din, Waheed Iqbal   +3 more
openaire   +2 more sources

Ribavirin: pharmacology, multiple modes of action and possible future perspectives

Future Virology, 2019
Ribavirin is a unique guanosine analog with broad-spectrum activity against many RNA and DNA viruses. In addition to its mutational properties, ribavirin exerts extensive perturbation of cellular and viral gene expression.
K. Nyström, J. Waldenström, Ka-Wei Tang, M. Lagging   +3 more
semanticscholar   +1 more source

A Focus on Natural Autophagy Modulators as Potential Host‐Directed Weapons Against Emerging and Re‐Emerging Viruses

Medicinal Research Reviews, EarlyView.
ABSTRACT Autophagy is a highly conserved intracellular process involved in maintaining homeostasis and in the degradation of damaged organelles and external pathogens. Nature provides complex and varied reservoirs of scaffolds and chemical entities that may have a pivotal role in the search for new therapeutic leads.
Ilaria Cursaro, Sara Rossi, Stefania Butini, Sandra Gemma, Gabriele Carullo, Giuseppe Campiani   +5 more
wiley   +1 more source

Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial

Annals of Hepatology, 2003
Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection.
Francisco Bosques-Padilla, MD, Rafael Trejo-Estrada, MD, Octaivio Campollo-Rivas, MD, Carlos Cortez-HernÁndez, MD, Margarita Dehesa-Violante, MD, Héctor Maldonado-Garza, MD, Raúl Pérez-Gómez, MD, Armando Cabrera-Valdespino, MD   +7 more
doaj   +1 more source

Introduction to the database “efficacy of different treatment modalities for lower respiratory tract infections in children”

Pediatric Discovery, EarlyView.
This article introduces a national, multicenter, prospective, non‐interventional, observational registry study, which established a comprehensive and sustainable database of lower respiratory tract infection in children. This database will help improve the scientific research efficiency of clinicians and facilitate the exploration of underlying ...
Yu Deng, Bing Hu, Yingxue Zou, Zhengxiu Luo, Guangli Zhang, Jinhai Ma, Changshan Liu, Xiaoyan Dong, Huifen Zi, Chuangli Hao, Rongjun Lin, Xiangrong Zheng, Bingfei Li, Fenhua Chen, Mei Fang, Weimin Tian, Zhiqiang Zhuo, Deyu Zhao, Zhimin Chen, Yuejie Zheng, Jingyang Zheng, Yong Yin, Qiuyu Tang, Liqun Wu, Li Gu, Jinzhun Wu, Liyi He, Tao Ai, Ning Wang, Minjun Zhang, Hailin Zhang, Hanmin Liu, Youxiang Zhang, Jianguo Hong, Zhiying Han, Yunbo Mo, Hongmei Qiao, Zhiliang Tian, Zengni Li, Quan Lu, Enmei Liu   +40 more
wiley   +1 more source

Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]

BMC Gastroenterology, 2003
Background Evidence based medicine depends on unbiased selection of completed randomized controlled trials. For completeness it is important to publish all trials.
Delwaide Jean, Michielsen Peter, Nevens Frederik, Adler Michael, Brouwer Johannes T, Veldt Bart J, Hansen Bettina E, Schalm Solko W   +7 more
doaj   +1 more source

Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria

BMJ Open, 2020
Introduction Lassa fever (LF) is a severe and often fatal systemic disease in humans and affects a large number of countries in West Africa. Treatment options are limited to supportive care and the broad-spectrum antiviral agent ribavirin.
Michael Ramharter, Osahogie Edeawe, Peter Akhideno, Gloria Eifediyi, Till F Omansen, Christine Wagner, Francisca Sarpong, Till Koch, Sebastian Wicha, Florian Kurth, Sophie Duraffour, Lisa Oestereich, Meike Pahlmann, Sylvanus Okogbenin, Ephraim Ogbaini-Emovon, Stephan Günther, Mirjam Groger   +16 more
doaj   +1 more source